Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli

被引:308
作者
Rodriguez-Bano, Jesus [1 ]
Alcala, Juan C. [2 ]
Cisneros, Jose M. [1 ]
Grill, Fabio [3 ]
Oliver, Antonio [5 ]
Horcajada, Juan P. [6 ]
Tortola, Teresa [7 ]
Mirelis, Beatriz [8 ]
Navarro, Gemma [9 ]
Cuenca, Maria [10 ]
Esteve, Maria [11 ]
Pena, Carmen [12 ]
Llanos, Ana C. [1 ]
Canton, Rafael [4 ]
Pascual, Alvaro [2 ]
机构
[1] Hosp Univ Virgen Macarena, Secc Enfermedades Infecciosas, Seville 41009, Spain
[2] Hosp Univ Virgen Macarena, Microbiol Serv, Seville 41009, Spain
[3] Hosp Univ Ramon & Cajal, Serv Enfermedades Infecciosas, Madrid, Spain
[4] Hosp Univ Ramon & Cajal, Microbiol Serv, Madrid, Spain
[5] Hosp Son Dureta, Microbiol Serv, Palma de Mallorca, Spain
[6] Hosp Clin Barcelona, Serv Enfermedades Infecciosas, Barcelona, Spain
[7] Hosp Valle De Hebron, Microbiol Serv, Barcelona, Spain
[8] Hosp Santa Creu & Sant Pau, Microbiol Serv, Barcelona, Spain
[9] Corp Sanit Parc Tauli, Unidad Epidemiol, Sabadell, Spain
[10] Hosp Ribera, Microbiol Serv, Valencia, Spain
[11] Hosp Univ Germans Trias & Pujol, Unidad Med Preventiva, Badalona, Spain
[12] Hosp Univ Bellvitge, Serv Enfermedades Infecciosas, Barcelona, Spain
关键词
D O I
10.1001/archinte.168.17.1897
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Extended-spectrum beta-lactamase (ESBL)producing Escherichia coli is an increasingly important group of community pathogens worldwide. These organisms are frequently resistant to many of the antimicrobial agents usually recommended for the treatment of infections caused by E coli, such as penicillins, cephalosporins, fluoroquinolones, and trimethoprim-sulfamethoxazole. Data concerning risk factors, clinical features, and therapeutic options for such infections are scarce. Methods: A case-control study was performed to investigate the risk factors for all types of community-acquired infections caused by ESBL-producing E coli in 11 Spanish hospitals from February 2002 to May 2003. Controls were randomly chosen from among outpatients with a clinical sample not yielding ESBL-producing E coli. The clinical features of these infections were investigated in the case patients. The efficacy of fosfomycin tromethamine and amoxicillin-clavulanate potassium was observationally studied in patients with cystitis. Results: A total of 122 cases were included. Risk factors selected by multivariate analysis included the following: age older than 60 years; female sex; diabetes mellitus; recurrent urinary tract infections (UTIs); previous invasive procedures of the urinary tract; follow-up in outpatient clinic; and previous receipt of aminopenicillins, cephalosporins, and fluoroquinolones. Urinary tract infections accounted for 93% of the cases; 6% of the patients were bacteremic and 10% needed hospitalization. The cure rate of patients with cystitis was 93% with fosfomycin therapy (all isolates were susceptible); among patients treated with amoxicillin-clavulanate, cure rates were 93% for those with susceptible isolates (minimum inhibitory concentration <= 8 mu g/mL) and 56% for those with intermediate or resistant isolates (minimum inhibitory concentration >= 16 mu g/mL) (P = .02). Conclusions: In predisposed patients, ESBL-producing E coli is a notable cause of community-acquired infection, and particularly UTI. Fosfomycin and amoxicillin-clavulanate appear to be effective for cystitis caused by susceptible isolates.
引用
收藏
页码:1897 / 1902
页数:6
相关论文
共 29 条
[1]  
*AG CAL SIST NAC S, 2005, EST EST SAN REG INT
[2]   Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections:: A nationwide surveillance study [J].
Andreu, A ;
Alós, JI ;
Gobernado, M ;
Marco, F ;
de la Rosa, M ;
García-Rodríguez, JA .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2005, 23 (01) :4-9
[3]   Influx of extended-spectrum β-lactamase producing enterobacteriaceae into the hospital [J].
Ben-Ami, R ;
Schwaber, MJ ;
Navon-Venezia, S ;
Schwartz, D ;
Giladi, M ;
Chmelnitsky, I ;
Leavitt, A ;
Carmeli, Y .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (07) :925-934
[4]   Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases [J].
Calbo, E ;
Romaní, V ;
Xercavins, M ;
Gómez, L ;
Vidal, CG ;
Quintana, S ;
Vila, J ;
Garau, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) :780-783
[5]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[6]  
Clinical and Laboratory Standards Institute, 2005, M100S15 CLSI
[7]   Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients [J].
Colodner, R ;
Rock, W ;
Chazan, B ;
Keller, N ;
Guy, N ;
Sakran, W ;
Raz, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (03) :163-167
[8]   In vitro activity of fosfomycin against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Comparison of susceptibility testing procedures [J].
de Cueto, M ;
López, L ;
Hernández, JR ;
Morillo, C ;
Pascual, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :368-370
[9]   Activity of fosfomycin against extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae [J].
de Cueto, Marina ;
Hernandez, Jose R. ;
Lopez-Cerero, Lorena ;
Morillo, Concepcin ;
Pascual, Alvaro .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (10) :613-616
[10]   Community-acquired extended-spectrum β-lactamase producers, United States [J].
Doi, Yohei ;
Adams, Jennifer ;
O'Keefe, Alexandra ;
Quereshi, Zubair ;
Ewan, Lindsay ;
Paterson, David L. .
EMERGING INFECTIOUS DISEASES, 2007, 13 (07) :1121-1123